P-187 Management of chemo-induced nausea/vomiting (CINV) in medical oncology department Hassan II University of Fez (Morocco)

Abstract

Introduction: Chemotherapy induced nausea and vomiting (CINV) are frequent and heavily affect the quality of life of patients. They are multifactorial. Better control of these CINV must be maintained from the first cycle of chemotherapy. The aim of this study was to evaluate the different parameters involved in the CINV occurring after the first cycle of chemotherapy. Methods: This is a prospective study of 150 patients followed at the medical oncology department of the Hassan II University Hospital of Fez from January 10 to June 10, 2015. Patients completed on day one of the second cycle of chemotherapy the Arabic versions of 3 questionnaires: the anxiety and depression questionnaire (HADS), the quality of life questionnaire (EORTC QLQ-C30) and the CINV questionnaire (MAT questionnaire MASCC). Data were analyzed with SPSS software version 20.0. Results: The mean age of patients was 45 ± 15 years. Male gender was predominant (68% of cases). 30% of patients had toxic ingestion history. Location of the primary tumor was mainly in breast (35% of cases), head and neck (29%) and lung (15%). 45% of patients were aware of the occurrence of vomiting before the 1st treatment, and only 65% received antiemetic therapy on day 1. 85% of patients presented CINV after the first cycle. Among these patients, 65% were female, 55% had delayed vomiting and 85% were of type II of the NCI-CTCAE classification (National Cancer Institute-Common Terminology Criteria for Adverse Events). CINV were associated with impaired quality of life in 97% of cases, with r = -0.245 in case of acute vomiting, r = -0,422 in case of acute nausea, r = -0,398 for late vomiting and r = -0,498 in case of delayed nausea ( p < 0.05). Conclusion:The results of this study suggest that nausea and vomiting remains a major problem for cancer patients. This is consistent with results from other published studies. Several parameters are incriminated such as the patients' information and support and primary prophylaxis. These parameters can minimize the impact of these adverse reactions.